Category Archives: Human Longevity

As a local general practitioner, I wish to support the sentiment expressed by Sue Saw in last weeks letter section (Question all levels of government on pandemic, Pique, March 11).

For the past 12 months I too have been profoundly disturbed by the medias role in creating and maintaining a constant state of hypervigilance regarding COVID-19.

Measured in terms of threat to quality human life years, coronavirus would not make the top 10 on my personal list of preventable or modifiable risks to human health and longevity. In fact, I have yet to lose a single patient to the disease.

But I do worry about how many clients I may ultimately lose due to this irrational overreaction to the disease, akin to an auto-immune response, bordering on anaphylaxis.

The media has done a brilliant job of documenting the daily death toll related to COVID-19, but the vast collateral damage of the drastic measures imposed to limit its spread will likely never be tabulated.

For most members of the population, conditions such as hypertension, diabetes, coronary artery disease and cancer are all greater threats than is the current virus in circulation. Yet panic over the possibility of contracting infection has led to serious delays in diagnosing and managing these conditions for many individuals.

In the elderly, social integration has long been recognized as vital to maintaining mental and physical health, and yet they have been denied this basic right for over a year.

At any demographic level, anywhere in the world, the economic downturn due to political responses to the pandemic is causing and aggravating poverty, another factor intimately linked to poor health and premature death.

Fear of the virus has also discouraged ridership on public transport, even though it is 100 times safer than personal motor transportation, in terms of risk of accidental injury or death. I would guess that the average age of the pandemics collateral victims is well under that of the average age of those who have succumbed to the infection, magnifying the ultimate tally of unnecessary life-years lost.

Like all other living things, human beings have always been dying of infectious disease. History is a litany of waves of epidemics and pandemics, most far more deadly than the current one. I find it extraordinary and hypocritical that we suddenly have become so risk-adverse to a virus while we continue to blissfully play Russian roulette with so many fundamental life-sustaining elements of our biosphere, including climate stability.

Depending on the evolution of coronavirus strains, herd immunity and vaccination programs may ultimatelyprovide at least temporary reprieve from propagation of the disease itself, but what I would really like to see is development of a vaccine versus paranoia and mass hysteria, to help us achieve herd immunity to brainwashing by fear-mongeringpoliticians and members of the media.

Thomas DeMarco MD // Whistler

The rest is here:
LETTER TO THE EDITOR: We need herd immunity against brainwashing politicians - Pique Newsmagazine

While a person cant stop ageing, you can, in a way, slow it down. There is no easier way to do so than through healthy lifestyle habits. By consuming raw honey moderately, you could help increase your lifespan, experts say.

Honey is widely accepted as food and medicine by all generations, traditions and civilisations, both ancient and modern.

Honey is a sweet, flavourful liquid food of high nutritional value and immense health benefits.

Some of the vitamins found in honey include ascorbic acid, pantothenic acid, niacin and riboflavin; along with minerals such as calcium, copper, iron, magnesium, manganese, phosphorus, potassium and zinc.

READ MORE:Hair loss treatment: Green tea could prevent balding and support hair growth

In a study published in the National Library of Health, the effects of honey and its mechanisms of action on the development and progression of cancer was analysed.

The study noted: Honey is a natural product known for its varied biological or pharmacological activities-ranging from anti-inflammatory, antioxidant, antibacterial, antihypertensive to hypoglycaemic effects.

Effects of honey have been thoroughly investigated in certain cancers such as breast, liver and colorectal cancer cell lines. In contrast, limited but promising data are available for other forms of cancers including prostate, bladder, endometrial, kidney, skin, cervical, oral and bone cancer cells.

Honey is highly cytotoxic against tumour or cancer cells while it is non-cytotoxic to normal cells.

Thus, honey may serve as a potential and promising anticancer agent which warrants further experimental and clinical studies.

DON'T MISSDoes Pfizer vaccine cause blood clots?[INSIGHT]Alcohol-related liver disease: Three signs[TIPS]Bowel cancer: Narrow poo is a visual sign[ADVICE]

Cardiovascular diseases are the leading causes of death worldwide.

However, the use of honey may help to address each of the factors contributing to heart disease.

For one, elevated levels of poor low-density lipoprotein (LDL) cholesterol raise the risk of heart disease.

This is because it can lead to blocked arteries, which then increases the risk of heart attacks and strokes.

However, studies have found that honey not only helps to lower the levels of LDL cholesterol, but it also serves to raise the levels of good high-density lipoprotein (HDL) cholesterol.

Produced in New Zealand by bees that pollinate the Manuka tree, this form of honey is known for its rich nutritional value as it contains high levels of amino acids, B vitamins, calcium, iron, magnesium and other essential nutrients making it one of the healthiest types of honey out there.

While regular honey may contain the same nutrients, the reason as to why the Manuka one has a better reputation is because it contains additional compounds that make it even more beneficial for human health.

All kinds of honey have been used as natural antibiotics throughout the centuries. In recent years, researchers have discovered that honeys power to kill germs comes from hydrogen peroxide produced with the help of a bee enzyme.

Manuka honey takes this a step further by attacking germs with a substance called MGO. Found in the nectar of some Manuka plants, this substance helps heal both minor and chronic wounds.

Anti-ageing is about postponing the onset of old age, while maintaining strong and healthy body.

Raw Manuka honey not only protects ones overall health, it also boosts your metabolism.

Having a sluggish metabolism and slow fat burning are typical of old age.

By replacing sugar with honey, you will speed up the rate at which you burn calories and thus lose weight natural way.

Studies have also indicated that by consuming raw honey you will have better endurance when it comes to exercising.

By losing weight, reducing your risk of cancers and heart disease you can help boost your longevity.

Read the rest here:
How to live longer: Honey to help reduce cancer risks, increase memory & boost longevity - Express

The days of cream and sugar are over. There's a new ingredient in town that everyone is putting in their coffeeand it's not just for flavor: adaptogens.

"Adaptogens are nontoxic herbal pharmaceuticals which claim to help us better cope with (or increase our resistance to) mental or physical stress, improving physical and mental performance, and possibly supporting the immune system," says Silvia Carli, MS, RD, registered dietitian for 1AND1 LIFE. (Related: 11 Healthy Foods That Make You Smarter, According to Doctors.)

Many of the new canned and bottled coffee drinks use adaptogens to help deliver all the focus of caffeinated coffee but with less of a crash or jitters while providing stress-relieving benefits.

While adaptogens have been used for thousands of years in traditional herbal medicine, they're only recently becoming more commonplace as more research is being done to confirm their benefits.

"Functional mushrooms are finally having their moment in the public spotlight, in large part due to the growing amount of research into their health benefits as well as their applications in food," says Kerry Hughes, MS, CNC, a certified clinical nutritionist, ethnobotanist and herbalist who is on the Scientific Advisory Board for Good Pharma.

If you've ever felt too jittery after drinking plain coffee, you might be interested in drinking adaptogen-enriched coffee, which is often much lower in caffeine than a traditional cup of joe while also having the benefits of functional mushrooms.

As adaptogens have been linked to lower stress levels, adding them to coffee may help to lower our level of stress and burnout in an easy wayby adding it to something we drink every day anyway.

"The search is on for more natural and accessible ways to manage stress that may also have additional health benefits such as increased cognitive function as well as boost immunity," says Aimee Plauche, RD, an advising registered dietitian for ICONIC. And adaptogens are one of the ways to do this.

These mushrooms and roots have been used in Chinese and Ayurvedic medicine for thousands of years, but we're just starting to do more research into adaptogens to prove their benefits.

"While more research is needed, studies on the utility of certain adaptogens seem promising," saysKylie Ivanir, MS, RD, a registered dietitian atWithin Nutrition.

"Studies conducted in animals and in human cell samples have shown that adaptogens may indeed demonstrate neuroprotective activity, have anti-fatigue and antidepressant properties, and can serve as a stimulant for the central nervous system. Studies have shown that particular adaptogens, such as Rhodiola extract, can improve cognitive function and combat fatigue," says Ivanir.

She adds that larger research studies completed on humans are needed to determine the efficacy of each particular adaptogen.

There are a few common adaptogens that are used more frequently in coffee:

Adaptogen coffee has some great added benefits, but experts say you shouldn't be drinking it as a solution to your underlying health problems.

"It's not that adaptogens would not improve your quality of life if you are extremely stressed, but is that the factor that is going to make the biggest difference?" says Carli.

She recommends taking a closer look at your daily habits: "I want to invite the readers to reflect on a couple of points: are there other adjustments that we can make in our daily routine to ease the stress in our lives? For example: are we practicing self-care, eating an overall healthy, varied, and balanced diet without overly processed foods? Are we sleeping well? Do you journal? Do you exercise? Do you have an outlet to talk about your stressors?" says Carli.

If you're dealing with a lot of stress, it might be best to combine your adaptogen coffee with other stress-reducing habits.

Adaptogens aren't for everyone. And it's not just about personal preferencetaking adaptogens isn't safe for certain people.

"It is important to note that certain adaptogens may not be safe for everyone including pregnant women, so it is always best to consult with your healthcare provider," says Ivanir.

As with any supplement, Carli notes that you should make sure the adaptogens you're consuming are safeespecially considering that these are a fairly new product.

"When new supplements get on the market quickly due to new trends (sometimes poorly supported by research), the process of testing for quality and purity is not always ideal and thorough, which means that we are not certain of the actual contents of that supplement and it could turn out being harmful to health," says Carli. (Related: 6 Popular Supplements That Don't Actually Work, According to Experts.)

That's why Ivanir tells that it's important to choose reputable brands that have been third-party tested to ensure there are no contaminants or heavy metals.

And although the benefits of adaptogens sound enticing, it's always good to keep in mind that it's best to not rely on taking these ingredients alone for their benefits without following a well-balanced diet.

"Adaptogens should not take the place of a balanced diet, physical activity, and any necessary medications, they may be used as a supplement to support overall health," adds Ivanir.

So in addition to drinking adaptogen coffee, you can also try these22 Proven Tricks That Melt Stress.

For more healthy eating news, make sure to sign up for our newsletter!

Read more here:
The One Ingredient Everyone's Adding to Their Coffee | Eat This Not That - Eat This, Not That

March 19, 2021 @ 13:28 by Chloe Holmes

Together with VOICE, The UKs National Innovation Centre for Ageing will launch their very first citizen-led community in the US.

Through a commercial agreement, VOICE (Valuing Our Intellectual Capital & Experience) and the UKs National Innovation Centre for Ageing (NICA) have set up a partnership with a non-profit organisation called amazing.community.

Headquartered in New Jersey (US) the amazing.community supports women aged 45+ as they navigate the present and future of work in this digital world; the organisation offers cutting edge skills building opportunities, curated resources, and an open virtual door for women 45+ to connect meaningfully with each other.

This new partnership will help build a more diverse VOICE community and facilitate cultural exchanges between US and UK. NICA and amazing.community will work together to explore the impact of technology at work, ageism, gender equality, cultural differences and the many issues and challenges that need to be addressed to ensure women over 45 thrive in the workplace now and in the future.

All this is building a deep global knowledge and rich consumer insights on healthy ageing. It gives businesses, entrepreneurs, innovators, and policy makers a novel and unique source of data and insights, building the evidence base to rapidly inform the development of new products and services helping people to live well for longer and tapping into a billion-pound longevity economy.

NICA, who are based within Newcastle University, UK on Newcastle Helix, is the UK home of Ageing Intelligence, which brings together data driven insight and human experiences to help bring new products, business models and services to market. VOICE is part of NICA and leads dialogue with citizens on what is needed for healthy ageing.

VOICE currently has a citizen network of more than 8,000 people the UK and this expansion is part of NICAs strategy to provide services and insight on ageing at a global level. It is intended that this business model will be replicated in other countries around the world, building a broader repository of data and insight to empower new business opportunities and ideas.

Professor Lynne Corner, chief operating officer at NICA and director of VOICE said: This marks the first step in our global ambitions for the VOICE community and we are thrilled to partner with the wonderful team at amazing.community and support ageing innovation in the US.

This is a strategic decision to develop a more culturally and gender diverse community to generate broader, deeper, richer insights and cultural exchanges between individuals from all over the world. It will provide to clients, business and policy makers a novel and unique source of insight.

This new business model is not only commercially viable, but also a way to empower parallel communities to come together and amplify their voices sharing experiences, exchanging insights, and building on common ground. Our plans will not only support international longevity economies but make a lasting impact on peoples lives helping them live well for longer.

amazing.community will be able to take advantage of ten years of operational expertise in community engagement from the VOICE network in the UK. Branded as Amplified by VOICE, amazing.community has customized the VOICE digital platform to engage and grow their existing community as well as to invite more robust collaboration with companies, non-profits and other organisations.

Dr. Ashley Ater Kranov, executive director of amazing.community, said: Im thrilled to announce our global partnership with VOICE. It has been nearly a year in the making and we are beyond ready to bring our communities together.

This partnership forwards one of our strategic initiatives: to establish close ties with a center for aging known for applied research, community engagement, and a commitment to transforming individual lives and impacting policy. Our collaboration will allow each of our communities to participate in tech skills building opportunities, quality of life research studies and special interest group discussions offered by both organizations.We believe doubling our offerings and opening the door to an international community will meaningfully enhance our efforts to expand the work horizon for women 45+ who are looking to re-enter the workforce, pivot to a new career or start their own businesses.

To celebrate this global partnership, and to bring both communities together for an engaging cross Atlantic conversation, they will watch the exclusive premiere of the film Les Dames (Ladies).

The acclaimed Swiss film Ladies by directors Stphanie Chuat, Vronique Reymond is a movie that reveals the passions, intimacy, and desires of five women who, at the dawn of their 60s or older, dream of their future. This will be a first-world premiere and will also mark the start of a joint research piece on love, life, companionship for women in later life.

For more information or to sign up to be part of the VOICE community visit https://www.voice-global.org/about/ (UK) or https://amazing.community (US).

Here is the original post:
Global expansion for UK National Innovation Centre with a new VOICE in the US - North East Times

EDISON BIO is expanding human health potential.

HOUSTON (PRWEB) March 19, 2021

Houston health tech company EDISON BIO has launched what may be the most comprehensive executive health exam on the planet. This new physical of the future aggregates a wide array of health data to create a truly universal digitalization of patients minds and bodies focused on improving longevity and performance. EDISON BIOs Artificial Intelligence, combined with a team of medical experts, analyzes health changes at the first signs of detection long before they have the chance to progress into serious health concerns. By analyzing this personalized data, EDISON BIO can uncover potential health risks and create an educational, highly personalized health strategy focused on optimizing diet, exercise, and lifestyle to improve overall performance and longevity. This approach aims to empower people to achieve the most in-depth understanding of all areas of their health in a way never before imagined.

Despite all the advances of modern medicine, todays healthcare system still largely takes a reactionary approach, catching disease only after symptoms manifest. By that time, it is often too late to reverse the resulting damage. The team at EDISON BIO believes that no one should have to wait until their disease becomes too harmful for treatment and is accelerating access to the latest in medical detection technology.

In contrast to the routine exam and minimal blood work done by many doctors today, EDISON BIO uses the latest technology to collect extensive data including full-body MRI imaging, a full array of genomic technology including whole genome sequencing, extensive blood analysis, and diet, lifestyle, and mental health evaluations to determine current and future health risks. This scientifically quantified data empowers members with confidence and peace of mind as to the comprehensive state of their health.

EDISON BIOs founder realized the need for proactive awareness of health risks when a cancer screening technology saved his mothers life. Around the same time, a family friend passed away after cancer was detected too late. He and his team have spent nearly twenty years researching and experimenting with medical technology to make medicine more personalized and less reactionary in nature. He believes that it will change the way people engage with their health through anticipating concerns early on and empowering people with personalized tools to achieve their optimum health.

EDISON BIO conducts exams at their members preferred location, including their homes, corporate offices, or wherever they are requested. After the biomarkers are analyzed, they offer an easy-to-understand educational plan to address concerns as well as rapid access to the worlds leading experts if a rare condition or disease is detected.

EDISON BIO is using evidence-based, data-driven technology to expand human health potential. Named in homage to Thomas Edisons invention of the light bulb, EDISON BIO is illuminating the future of healthcare in the twenty-first century by providing a more personalized, preventive, and data-driven approach to health.

EDISON BIO Contact: http://www.edisonbio.com / support@edisonbio.com / Phone: 888-366-0123

Share article on social media or email:

See original here:
EDISON BIO Launches Advanced Executive Health Exam For Early Detection Of Health Risks - PR Web

Light and heat sensors on a building at the University of Southern Denmark adjust shutters to optimize indoor conditions.

The Smart City Index (1) defines a smart city as an urban setting that applies technology to enhance the benefits and diminish the shortcomings of urbanization for its citizens. The top-ranked city, Singapore, has addressed urban challenges with information technology since 2014 through its Smart Nation Initiative (2). The influence of technology is reflected in the city's open platform for sharing energy data, crowd-sourced location data for smart navigation, and even online forums for citizen participation in policy-making (2). The smart city concept requires the acquisition of massive amounts of data in real time, and large networks of smart devices must spread the burden of communication and processing evenly across the network to prevent information overload at its center. Opportunities to solve this challenge have recently emerged through the development of increasingly smart materials that can sense, process, and respond to environmental stimuli without centralized resources.

A recent market analysis predicted that the number of connected devices, sensors, and actuators that constitute the Internet of Things (IoT) will reach more than 46 billion in 2021, driven largely by reduction in hardware costs to as little as $1 per device (3). Inexpensive connected sensing devices measuring strain, temperature, and humidity (4), as well as the enhancement of indirect sensing methods that use computer vision and crowd-sourcing (5), provide vast amounts of data to quantify the built environment (6). The ability to continuously monitor the physical state of infrastructure with high resolution in time and space has exciting implications for sustainability and equity. Quantitative, data-driven decision-making can enable predictive maintenance in place of conventional intuition-based workflow, although such automated systems can also learn to replicate human biases (7).

However, efficient decision-making based on these data streams becomes limited by the burden of transmitting and processing the raw, unprioritized data. As the number of connected devices rises, smart cities have shifted from a hierarchical network architecture based on cloud computing to a more decentralized information ecosystem. In this so-called fog computing model, data processing is performed at the edge of the network to avoid costly communication with a central cloud server (8). Alternatively, mist computing represents an even more extreme paradigm in which data processing is handled by microprocessors attached directly to the sensors and actuators. One advantage of mist computing is a reduced burden on communications systems by constraining information to a need-to-know basis. This approach has an added sustainability benefit because communication among IoT devices accounts for as much as five times the power consumption necessary for the computation itself (9).

Infrastructure decision-making can benefit from distributed sensor data if data can be processed efficiently. Data management can benefit from need-to-know processing strategies, as illustrated for the construction of a subway system, where tunneling can create ground-surface subsidence that can undermine an overlying building. At the city scale, analysis of these data can lead to decisions to mitigate subsidence impact, such as stopping tunneling or adding underlying support.

Orthogonal to these advances in IoT technology, multifunctional and responsive materials have been designed to substantially alter their shape or properties in response to external stimuli. When taken to the extreme, this concept results in living materials, which use biological organisms (10) as highly efficient chemical machines for sensing and responding to their environment. Such materials are engineered to sense and regulate their state at the microscopic scale to effect macroscopic structural or functional changes. A common function of smart or living materials is self-healing to improve the service life of a larger structure in support of its sustainability. For example, bacteria-triggered self-healing represents one of the most popularized concepts in living cementitious materials. Extensive research has been conducted on the use of extremophiles and engineered bacteria to imbue materials with the self-sensing capacity needed to trigger these self-healing properties (10).

In effect, these smart and living materials participate in an extreme version of the mist-computing model for structural health monitoring. Chemical gradients in the cement are detected, interpreted, and acted upon by means of incredibly low-power sensing and response mechanisms without increasing the communication and processing burden on the built environment. This latter point is critical because the electronic sensing and transmission of millimeter-scale chemical gradients across an entire smart city would absolutely overwhelm digital data processing systems. Information at this small scale is also irrelevant to decisions being made for an entire city block, so restricting it to an appropriate level reduces the cognitive load on stakeholders such as building managers and government policymakers (see the figure). This approach is analogous to how the human nervous system coordinates the contraction of many millions of cells through a hierarchy of control structures, rather than by consciously addressing individual muscle fibers.

Smart materials can also process data without the assistance of active biological matter. A fascinating example of computation in material substrates is the recent demonstration of photonic metamaterials (internally structured materials) that can solve complex mathematical equations (11). These devices exploit diffractive optics to leverage material microstructure into passive, all-optical transformations. A complementary idea is that of mechanologic, in which a mechanical metamaterial deforms in a preprogrammed way to combine computation and actuation (12). Given the rapid advancements in design and fabrication of these extraordinary materials, a next generation of smart materials may emerge with programmed thermal, optical, and mechanical responses acting as a self-sensing, self-actuating smart faade, or as a solar tracker to improve the efficiency of photovoltaic energy harvesting (13).

With connected sensors being deployed to provide real-time structural health monitoring of critical infrastructure [e.g., bridges, dams, residential and commercial buildings, and even temporary structures (14)], managing the flood of data is more important than ever to prevent smart cities from suffering analysis paralysis. Smart and living materials may push data processing to previously unimagined extremes, with the literal foundations of the built environment acting as analog-computing substrates. This approach should offer pronounced advantages for sustainability, including increased longevity of infrastructure, reduced waste from the proliferation of electronic sensors, and reduced power consumption from communications. Moreover, the current challenge to implementation of mist-computing infrastructures is tied to their complexity and size, which are too great to manage by centralized systems (15). Thus, autonomous smart materials present a compelling tool in achieving robust and sustainable structural health monitoring in smart cities of the future.

Acknowledgments: We thank Z. Ounaies for inspiring our research collaborations.

See the original post here:
Smart cities built with smart materials - Science

New York, March 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Therapy Industry" - https://www.reportlinker.com/p06033005/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Abstract: - Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - Amid the COVID-19 crisis, the global market for Stem Cell Therapy estimated at US$127.5 Million in the year 2020, is projected to reach a revised size of US$242.3 Million by 2027, growing at aCAGR of 9.6% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 9.9% CAGR and reach US$228.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Autologous segment is readjusted to a revised 5.6% CAGR for the next 7-year period. - The U.S. Market is Estimated at $37.8 Million, While China is Forecast to Grow at 9% CAGR - The Stem Cell Therapy market in the U.S. is estimated at US$37.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.9 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 33 Featured) -

Read the full report: https://www.reportlinker.com/p06033005/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Stem Cell Therapy Competitor Market Share Scenario Worldwide: ( in %): 2020E Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Cord Blood / Embryonic Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Market Facts & Figures Market Analytics Table 37: USA Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CANADA Table 46: Canada Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

JAPAN Table 55: Japan Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CHINA Table 64: China Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

EUROPE Market Facts & Figures Market Analytics Table 73: Europe Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

FRANCE Table 85: France Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

See the article here:
Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - GlobeNewswire

On arriving in London to seek his fortune, the rambunctious Scottish physician George Cheyne set about hobnobbing in coffee houses and taverns, where he ate lustily and swallowed down much liquor. Before long, he had ballooned to nearly 450 pounds. In a state of existential crisis and discerning that his mortality was in the balance, he published a self-help manual, An Essay of Health and Long Life (1724). In this bestselling treatise, he singled out tea, coffee, chocolate and snuff as being especially detrimental to the human condition.

This seminal work, among others, spawned a tradition of books addressing the topic of longevity which continues to this day. While Cheyne and others contrived innumerable methods designed to maintain good health and extend lifespans, the process of aging has itself invariably been viewed as an immutable part of human nature.

No longer, says Andrew Steele in his entertaining and thoughtful book Ageless (Doubleday, 352 pages, $29). While we wither and become frail after a mere seven or so decades, the humble Galpagos tortoise bumbles on healthily into a 175-year dotage. Capturing this traitknown as negligible senescenceis the holy grail of aging research.

So if, as Mr. Steele contends, tortoises get old without getting elderly, might we not master biological immortality and become ageless too? Were this achievable, the existence of a bristlecone pine tree in Californias White Mountains, estimated to be an extraordinary 4,850 years old, suggests that such potential extensions to our longevity might be more than mere tweaks. The fact that lifespans of different species vary so greatlysome mayflies emerge, mate and die within 5 minutes, while bowhead whales can live for more than 200 yearsindicates that our lifespan is programmed by evolution, rather than restricted by insurmountable constraints.

Ageless follows biologist George C. Williamss simple evolutionary explanation for why we age, based on a phenomenon called antagonistic pleiotropy. Put simply, genes selected to facilitate early successful reproduction may have detrimental effects as we get older. In Mr. Steeles words, it looks as if evolution has traded our future health for increased reproduction. Were we able to roll the clock back and redesign ourselves, we would doubtless find alternative genetic circuits that did not have these unfortunate consequences. Perhaps one day, Mr. Steele conjectures, we will be able to reprogram our genomes to remove this legacy. Fortunately, there may be more immediately accessible paths to a longer life.

Originally posted here:
Ageless Review: The Long Run - The Wall Street Journal

High-skilled foreign nationals, including doctors and engineers, rally on Capitol Hill in ... [+] Washington, D.C., to protest long delays in getting green cards on September 18, 2007, in Washington, D.C. The employment-based green card backlog has worsened since 2007. (Photo by Jahi Chikwendiu/The Washington Post via Getty Images)

Without a change in immigration law, it will be sometime in the year 2216195 years from nowwhen the last person born in India waiting today in the employment-based immigrant backlog is expected to receive a green card. Barring advances in human longevity, businesses and high-skilled foreign nationals must rely on Congress to solve this problem and enact reasonable policies to welcome highly skilled people who want to become Americans.

The Scope of the Problem: H-1B and L-1 (intracompany transferee) are temporary statuses, meaning if someone wishes to remain in the United States, they must obtain an employment-based immigrant visa (or green card) that grants permanent residence. However, there is far greater demand for high-skilled individuals than the limited number of employment-based green cards allotted by Congress.

Since 1990, when Congress set the annual limit on employment-based immigrants at 140,000 (and 65,000 H-1B temporary visas), changes in technology have accelerated the demand for high-skilled technical labor. Congress established the current employment-based limits before the internet became a part of daily life. It also predates the iPhone, the iPad, YouTube, e-commerce, Netflix, Google, cloud computing and thousands of innovative companies and technologies that have come into existence and fueled the demand for high-skilled labor.

U.S. businesses would still need more scientists and engineers to grow and innovate even if the number of Americans earning degrees in science and engineering had explodedand it hasnt.

Between 1995 and 2015, full-time U.S. graduate students in electrical engineering decreased by 17%. The number of full-time U.S. graduate students in computer science increased by 45% from 1995 to 2015, while international graduate students increased by over 480%. (H-1B visa fees paid by employers have funded approximately 100,000 college scholarships for U.S. students in science and engineering.)

As of March 2020, the backlog in EB-1, EB-2 and EB-3the employment-based first, second and third preferenceswas 915,497, according to the Congressional Research Service (CRS).

Without Congressional action, notes CRS, the problem will grow worse: The total backlog for all three categories would increase from an estimated 915,497 individuals currently to an estimated 2,195,795 individuals by FY 2030.

Let that number sink in: Within a decade, more than 2 million people will be waiting in line, most for many years or even decades, for employment-based green cards. And there are indications this underestimates the problem.

Table 1 shows that in FY 2018 only about 4,500 Indians obtained permanent residence in the employment-based second preference and fewer than 6,000 received green cards in the employment-based third preference. (The National Foundation for American Policy obtained the data via a Freedom of Information Act request.)

CRS estimates the annual demand for employment-based green cards in the three preference categories is 262,376 (including dependents). This is based on petitions U.S. Citizenship and Immigration Services (USCIS) approved in FY 2018. CRS explains the backlog grew because there is a current limit of 120,120 green cards for the three employment-based immigration categories.

Another problem is that Congress established a per-country limit of 7% for each country that burdens mainly potential employment-based immigrants from India but also affects people born in China and the Philippines. The law, in effect, gives the same number of green cards for employment to India as it does Iceland.

In the employment-based second preference (EB-2): Under current law, and owing to a limited number of green card issuances, the current backlog of 568,414 Indian nationals would require an estimated 195 years to disappear, according to CRS. David Bier of the Cato Institute predicts about 186,038 Indian immigrants will die . . . before they receive green cards even if they could remain in line forever.

By FY 2030, [the] estimated wait time would more than double, according to CRS. Under S. 386, the estimated wait time for newly approved EB-2 petition holders would shrink to 17 years, and in FY 2030, the wait time would be 37 years, the same as for all other foreign nationals.

S. 386 was a bill in the last Congress sponsored by Sen. Mike Lee (R-UT) that would have eliminated the per-country limit for employment-based immigrants. Rep. Zoe Lofgren (D-CA) wrote H.R. 1044 with Rep. Ken Buck (R-CO) and it passed the House in July 2019. The companion bill, S. 386, was blocked in the Senate for more than a year. It became a Christmas tree for extraneous immigration provisions. The Senate finally approved S. 386 near the end of the session but the House found the provisions to be objectionable and it did not become law. The bill would not have increased the number of employment-based green cards but would have reduced the wait times for those waiting the longest for permanent residence, particularly professionals from India.

Without any change in the law, CRS predicts: Currently, new Indian beneficiaries entering the EB-3 [employment-based third preference] backlog can expect to wait 27 years before receiving a green card. (The wait time would be much longer in the EB-2 category.)

Scientists and engineers waiting for their green cards may see their children who have lived in the United States for years be forced to leave the country when they age out of their place on a mother or fathers immigration application when reaching 21 years old. USCIS policies during the Trump administration caused many spouses of H-1B visa holders waiting for green cards to lose their work authorization due to long processing delays.

New Immigration Bill Would End the Employment-Based Backlog: The U.S. Citizenship Act, developed by the Biden administration, would eliminate the employment-based backlog within 10 years through various provisions, according to a National Foundation for American Policy (NFAP) analysis.

First, the bill would no longer count spouses and children toward the annual limit, which would approximately double the annual number of employment-based green cards. Second, the legislation increases the annual limit for family-sponsored immigrants and allows unused numbers from the family categories to be used by the employment categories. That means once the family backlog is eliminated, which NFAP predicts could happen within 5 or 6 years, backlog reduction in the employment-based categories would accelerate.

Third, the bill eliminates the per-country limit. Fourth, the legislation allows unused green cards from earlier years to be redirected to reduce family and employment backlogs.

The bill also contains a provision, which NFAP has recommended, to allow any individuals who wait at least 10 years with an approved immigrant petition to receive permanent residence without numerical limit. If Congress passed only this reform, it would help many people and bring certainty to otherwise interminable waits for many employment-based immigrants.

Related to the backlog, in its final days, the Trump administration published a final rule designed to price employment-based immigrants and H-1B visa holders out of the U.S. labor market. The regulation would boost required wages 23% to 41% depending on the occupation, according to an NFAP study. The regulation could block people waiting for green cards if the new required salary is too high for an employer to retain them in H-1B status. (Individuals can be extended in H-1B status while waiting for an employment-based green card.)

If the Biden administration keeps the rule, it would be a significant victory for former White House adviser Stephen Miller and opponents of immigration.

Numerous studies and private wage surveys show that there is no evidence high-skilled foreign nationals are paid less than comparable U.S. professionals. If employers were forced to pay high-skilled immigrants 41% more than comparable U.S. workers, one would expect critics would still claim the immigrants were paid less because that is typically the only argument put forward against high-skilled foreign nationals who work in America. Members of Congress are repeatedly told to believe the only value someone born in another country offers a U.S. business or the U.S. economy is a willingness to work for less money.

If we have learned one thing from the pandemic, it is how valuable immigrants are to America. Immigrants play key roles in the two companies responsible for the Covid-19 vaccines Americans are receiving to protect their lives. Modernas leaders, two cofounders and critical scientific personnel are immigrants, as are the chief executive (and chief science officer) of Pfizer and a key scientist (Katalin Karik) who made a crucial breakthrough on messenger RNA, as noted in a December 2020 article. Even the founders of Pfizer were immigrants.

We have blown the opportunity to maximize the incredible high-skilled immigrants in this country, said Sen. Kevin Cramer (R-ND) at a recent hearing. The backlog of green cards is immoral to me. Will this be the year moral outrage and economic sense lead to a solution for employment-based immigrants?

See the original post here:
Immigration Bill Shows Need To End Employment-Based Immigrant Backlog - Forbes

Anti-Senescence Therapy Market 2021: Latest Analysis

Los Angeles, United State,March 2021, The study published on the Anti-Senescence Therapy market is a systematic review that includes key parameters and indicators that are crucial to market understanding. The data from the years 2015 to 2020 is used to show the status and size of the market. The report also includes a total market value for the forecast period, along with the CAGR. The introductory chapter, along with the product description and market scope, provides an overview of the Anti-Senescence Therapy industry. The study also analyzes market dynamics in product-related matters along with developments in the growth of the industry.

Anti-Senescence Therapy Market 2021 Research report contains a qualified and in-depth examination of Anti-Senescence Therapy Industry. At first, the report provides the current business situation along with a valid assessment of the Anti-Senescence Therapy Market Analysis. This report is partitioned based on driving Anti-Senescence Therapy Market Top Key players, application and regions. The progressing Anti-Senescence Therapy economic situations are additionally discovered in the report.

Major Key Manufacturers ofAnti-Senescence Therapy Market are:Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan

Request Free Sample Reportwith Complete TOC and Figures & Graphs@https://www.mraccuracyreports.com/report-sample/205864

Market Segment by Type covers:Gene Therapy, Immunotherapy, Others

Market Segment by Applications can be divided into:Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Anti-Senescence Therapy market.

Production, consumption, revenue, market share, and growth rate are the key targets forAnti-Senescence Therapy Market forecast from 2013 to 2026 (forecast) in these regions:

Benefits of buying the report:

Impact Of COVID-19

The most recent report includes extensive coverage of the significant impact of the COVID-19 pandemic on theAnti-Senescence Therapy division. The coronavirus epidemic is having an enormous impact on the global economic landscape and thus on this special line of business. Therefore, the report offers the reader a clear concept of the current scenario of this line of business and estimates the aftermath of COVID-19.

You can buy the complete report@ https://www.mraccuracyreports.com/checkout/205864

There are 15 Chapters to display the Global Anti-Senescence Therapy market

Chapter 1, Definition, Specifications and Classification of Anti-Senescence Therapy, Applications of Anti-Senescence Therapy, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Anti-Senescence Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Anti-Senescence Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Anti-Senescence Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Anti-Senescence Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Gene Therapy, Immunotherapy, Others, Market Trend by Application Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan , Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Anti-Senescence Therapy ;Chapter 12, Anti-Senescence Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Anti-Senescence Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

GetExclusive Discount on this report @https://www.mraccuracyreports.com/check-discount/205864

About us:

MR Accuracy Reportsprovides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Contact Us:

Email:[emailprotected]

Website:www.mraccuracyreports.com

See the original post here:
Anti-Senescence Therapy Market Report Research Reports, Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis...